Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
發表日期: 2026-12-01
The Journal of dermatological treatment
MediLens 收錄日: 2026-05-23
This study evaluated the off-treatment disease control in patients with moderate-to-severe atopic dermatitis (AD) following 12 weeks of abrocitinib 200 mg. In the phase 3 JADE REGIMEN study, patients who achieved significant improvement were randomized to receive either placebo or continued treat...
在PubMed上閱讀